



Dr. Reddy's Laboratories Ltd.  
8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500 034, Telangana,  
India.

CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900

Fax : +91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

April 20, 2023

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

**Sub: Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023.**

We are enclosing herewith a copy of the yearly Compliance Certificate issued by the Company Secretary in Practice for the period from April 1, 2022 to March 31, 2023 under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

K Randhir Singh

*Company Secretary, Compliance Officer & Head-CSR*



**CERTIFICATE UNDER REGULATIONS 40(9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE YEAR ENDED 31<sup>st</sup> MARCH, 2023**

We have examined all Registers, files and other documents relating to Dr. Reddy's Laboratories Limited (Company) having its registered office at 8-2-337, Road No.3, Banjara Hills, Hyderabad-500034, Telangana, maintained by the Registrar and Share Transfer Agent (RTA), M/s Bigshare Services Private Limited having its office at 306, 3rd floor, right wing, Amrutha Ville, Opp. Yashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad-500082, pertaining to transfer of Equity Shares of the Company for the financial year from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023, for the purpose of issuing a Certificate as per Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Listing Agreement entered into by, Dr. Reddy's Laboratories Limited with National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and based on the information provided by the Company/RTA, we hereby certify that:

- A. the Company has delivered during the year ended on 31<sup>st</sup> March, 2023 letter of confirmation(s) in respect of requests received during the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023 for duplicate and transmission requests within stipulated time;
- B. the Company has delivered during the year ended 31<sup>st</sup> March 2023, letter of confirmation(s) in respect of the requests received during the period from 1st April, 2022 to 31st March, 2023 for exchange of shares and name deletion within stipulated time;
- C. the Company has not received any request for split, replacement/renewal, sub-division, consolidation, transfer, replacement, or endorsement of calls/allotment monies during the financial year from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023.

**For R & A Associates**

RAGHU BABU GUNTURU  
Digitally signed by  
RAGHU BABU GUNTURU  
Date: 2023.04.19  
12:23:40 +05'30'

**Place : Hyderabad**  
**Date : April 19, 2023**

**(G Raghu Babu)**  
**Partner**  
**FCS. No. 4448, C.P. 2820**  
**UDIN: F004448E000139682**